Published in Women's Health Weekly, December 23rd, 1996
The patented technology measures the amount of an isoform of ferritin (p43) bound to lymphocytes. Work published by Dr. Chaya Moroz, Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel, and others, has demonstrated that the p43 protein is elevated at an early stage in breast cancer.
"This patent paves the way for Oncor to develop a blood test for early (stage IIH) breast cancer, as well as in situ (localized) cancer, which may provide the opportunity to detect and treat breast cancer at an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly